Flibanserin and Regulatory Failure

Guest Post by Adriane Fugh-Berman On August 18th, 2015, the FDA approved flibanserin (brand name Addyi), a purported aphrodisiac that can drop blood pressure so precipitously that users sometimes pass out and require medical intervention to regain consciousness.  The labelling for flibanserin indicates that it is for: the treatment of premenopausal women with acquired, generalized hypoactive […]

Read More…